Topiroxostat APIs supplied by Loncom Pharma are a testament to the company's commitment to quality and innovation in the field of gout management. By inhibiting xanthine oxidase, Topiroxostat APIs reduce uric acid levels in the blood, offering a targeted treatment option for gout patients.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
